Prima Biomed (PBMD) PT Lowered to $7 at Maxim Group, Buy Maintained as LAG-3 + Keytruda Moves to Higher Dose
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Prima BioMed Announces First Clinical Data From Combination of IMP321 With Anti-PD1
December 29, 2016 4:06 AM ESTSYDNEY, AUSTRALIA -- (Marketwired) -- 12/29/16 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced interim data for its TACTI-mel (Two ACTive Immunotherapeutics in melanoma) clinical trial program for IMP321 in unresectable or metastatic melanoma patients. The Database Safety Monitoring Board (DSMB) confirmed that IMP321 is safe and well tolerated at the first dose level when used in combination with a PD-1 blocking antibody and dose escalation can continue as planned.
In this first-in-man combination Phase I study, IMP321 is combined with the PD-1 checkpoint inhibitor... More
